Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma
Open Access
- 3 November 2006
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 14 (3), 227-232
- https://doi.org/10.1038/sj.cgt.7701006
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Progress in hematopoietic stem cell transplantation in multiple myelomaCurrent Opinion in Hematology, 2005
- Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myelomaExperimental Hematology, 2004
- Enhanced Ouabain Resistance Gene as a Eukaryotic Selection MarkerHuman Gene Therapy, 2002
- Engraftment of Gene-Marked Hematopoietic Progenitors in Myeloma Patients after Transplant of Autologous Long-term Marrow CulturesHuman Gene Therapy, 1999
- HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-LeukemiaScience, 1997
- Retroviral Transfer of the nlsLacZ Gene into Human CD34+Cell Populations and into TF-1 Cells: Future Prospects in Gene TherapyHuman Gene Therapy, 1994
- Retroviral‐mediated gene transfer into human myeloma cellsBritish Journal of Haematology, 1994
- Retroviral-Mediated Gene Transfer of CD34-Enriched Bone Marrow and Peripheral Blood Cells During Autologous Stem Cell Transplantation for Multiple Myeloma. Huddinge Hospital and Karolinska Institute, Huddinge, SwedenHuman Gene Therapy, 1994
- Lack of IL‐1 secretion from human myeloma cells highly purified by immunomagnetic separationBritish Journal of Haematology, 1993
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993